JP2016534059A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016534059A5 JP2016534059A5 JP2016525063A JP2016525063A JP2016534059A5 JP 2016534059 A5 JP2016534059 A5 JP 2016534059A5 JP 2016525063 A JP2016525063 A JP 2016525063A JP 2016525063 A JP2016525063 A JP 2016525063A JP 2016534059 A5 JP2016534059 A5 JP 2016534059A5
- Authority
- JP
- Japan
- Prior art keywords
- acceptable salt
- compound
- pharmaceutical composition
- effective amount
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KFLQYBLSEZRKTN-MOPGFXCFSA-N CC(N(CC[C@H]1NC(C=C)=O)C[C@@H]1Nc1nc(ccc(-c(c(Cl)c(cc2OC)OC)c2Cl)c2)c2cn1)=O Chemical compound CC(N(CC[C@H]1NC(C=C)=O)C[C@@H]1Nc1nc(ccc(-c(c(Cl)c(cc2OC)OC)c2Cl)c2)c2cn1)=O KFLQYBLSEZRKTN-MOPGFXCFSA-N 0.000 description 1
- 0 CCN(C1O)c2cc(N[C@](CCCC3)[C@]3NC(C#C)=O)ncc2C=C1c(c(Cl)c(*)cc1OC)c1Cl Chemical compound CCN(C1O)c2cc(N[C@](CCCC3)[C@]3NC(C#C)=O)ncc2C=C1c(c(Cl)c(*)cc1OC)c1Cl 0.000 description 1
- ZAOOOJFIXJSQSK-QWHCGFSZSA-N CCN(c(nc(N[C@H](CCC1)[C@H]1NC(C=C)=O)nc1)c1N=C1c(c(Cl)c(cc2OC)OC)c2Cl)C1=O Chemical compound CCN(c(nc(N[C@H](CCC1)[C@H]1NC(C=C)=O)nc1)c1N=C1c(c(Cl)c(cc2OC)OC)c2Cl)C1=O ZAOOOJFIXJSQSK-QWHCGFSZSA-N 0.000 description 1
- NGHDVDVDUXSERF-LTWKBGODSA-N CCN(c1c(C=C2c(c(Cl)c(cc3OC)OC)c3Cl)cnc(N[C@H](CCC3)[C@H]3N(C[C@@H](C[C@@H]3NC(C=C)=O)OC[C@H]3Nc3nc(ccc(-c(c(Cl)c(cc4OC)OC)c4Cl)c4)c4cn3)C(C=C)=O)n1)C2=O Chemical compound CCN(c1c(C=C2c(c(Cl)c(cc3OC)OC)c3Cl)cnc(N[C@H](CCC3)[C@H]3N(C[C@@H](C[C@@H]3NC(C=C)=O)OC[C@H]3Nc3nc(ccc(-c(c(Cl)c(cc4OC)OC)c4Cl)c4)c4cn3)C(C=C)=O)n1)C2=O NGHDVDVDUXSERF-LTWKBGODSA-N 0.000 description 1
- ILXYIVJPIDOKJQ-JKSUJKDBSA-N CN(c1cc(N[C@H](COCC2)[C@H]2NC(C=C)=O)ncc1C=C1c(c(Cl)c(cc2OC)OC)c2Cl)C1=O Chemical compound CN(c1cc(N[C@H](COCC2)[C@H]2NC(C=C)=O)ncc1C=C1c(c(Cl)c(cc2OC)OC)c2Cl)C1=O ILXYIVJPIDOKJQ-JKSUJKDBSA-N 0.000 description 1
- JHMGYDVAEUYQHL-UHFFFAOYSA-N COc(cc(c(Cl)c1-c(cc2)cc3c2nc(NC2CCCCC2)nc3)OC)c1Cl Chemical compound COc(cc(c(Cl)c1-c(cc2)cc3c2nc(NC2CCCCC2)nc3)OC)c1Cl JHMGYDVAEUYQHL-UHFFFAOYSA-N 0.000 description 1
- WEYGASMDUSXWOC-MSOLQXFVSA-N COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@@H](CCCC2)[C@@H]2NC(C=C)=O)nc3)OC)c1Cl Chemical compound COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@@H](CCCC2)[C@@H]2NC(C=C)=O)nc3)OC)c1Cl WEYGASMDUSXWOC-MSOLQXFVSA-N 0.000 description 1
- NCKDVUYBTAQHDX-COYJEINXSA-N COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@@H](CCCC2)[C@H]2NC(/C=C\COc(c(Cl)c2-c4ccc5nc(N[C@@H](CNCC6)[C@@H]6NC(C=C)=O)ncc5c4)cc(OC)c2Cl)=O)nc3)OC)c1Cl Chemical compound COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@@H](CCCC2)[C@H]2NC(/C=C\COc(c(Cl)c2-c4ccc5nc(N[C@@H](CNCC6)[C@@H]6NC(C=C)=O)ncc5c4)cc(OC)c2Cl)=O)nc3)OC)c1Cl NCKDVUYBTAQHDX-COYJEINXSA-N 0.000 description 1
- BVDNESAVRVJTNC-CCLHPLFOSA-N COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@@H]([C@H](C2)NC(C#C)=O)c4c2cccc4)nc3)OC)c1Cl Chemical compound COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@@H]([C@H](C2)NC(C#C)=O)c4c2cccc4)nc3)OC)c1Cl BVDNESAVRVJTNC-CCLHPLFOSA-N 0.000 description 1
- WEYGASMDUSXWOC-QZTJIDSGSA-N COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](CCCC2)[C@@H]2NC(C=C)=O)nc3)OC)c1Cl Chemical compound COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](CCCC2)[C@@H]2NC(C=C)=O)nc3)OC)c1Cl WEYGASMDUSXWOC-QZTJIDSGSA-N 0.000 description 1
- WEYGASMDUSXWOC-ZWKOTPCHSA-N COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](CCCC2)[C@H]2NC(C=C)=O)nc3)OC)c1Cl Chemical compound COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](CCCC2)[C@H]2NC(C=C)=O)nc3)OC)c1Cl WEYGASMDUSXWOC-ZWKOTPCHSA-N 0.000 description 1
- GKQWMHRQOVMSIE-SJORKVTESA-N COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](CCOC2)[C@H]2NC(C=C)=O)nc3)OC)c1Cl Chemical compound COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](CCOC2)[C@H]2NC(C=C)=O)nc3)OC)c1Cl GKQWMHRQOVMSIE-SJORKVTESA-N 0.000 description 1
- JPCIRONPDKKKBK-DLBZAZTESA-N COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](CNCC2)[C@H]2NC(C=C)=O)nc3)OC)c1Cl Chemical compound COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](CNCC2)[C@H]2NC(C=C)=O)nc3)OC)c1Cl JPCIRONPDKKKBK-DLBZAZTESA-N 0.000 description 1
- MGZKYOAQVGSSGC-DLBZAZTESA-N COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](COCC2)[C@H]2NC(C=C)=O)nc3)OC)c1Cl Chemical compound COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](COCC2)[C@H]2NC(C=C)=O)nc3)OC)c1Cl MGZKYOAQVGSSGC-DLBZAZTESA-N 0.000 description 1
- FRVZTFULMVCLRE-HYVNUMGLSA-N COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](C[C@@H](C2)O)[C@H]2NC(C=C)=O)nc3)OC)c1Cl Chemical compound COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](C[C@@H](C2)O)[C@H]2NC(C=C)=O)nc3)OC)c1Cl FRVZTFULMVCLRE-HYVNUMGLSA-N 0.000 description 1
- AWQOOPSJCUIVQO-JKSUJKDBSA-N COc(cc(c(Cl)c1-c(cc2Cl)cc3c2nc(N[C@H](COCC2)[C@H]2NC(C=C)=O)nc3)OC)c1Cl Chemical compound COc(cc(c(Cl)c1-c(cc2Cl)cc3c2nc(N[C@H](COCC2)[C@H]2NC(C=C)=O)nc3)OC)c1Cl AWQOOPSJCUIVQO-JKSUJKDBSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895472P | 2013-10-25 | 2013-10-25 | |
| US61/895,472 | 2013-10-25 | ||
| US201461927782P | 2014-01-15 | 2014-01-15 | |
| US61/927,782 | 2014-01-15 | ||
| PCT/US2014/061974 WO2015061572A1 (en) | 2013-10-25 | 2014-10-23 | Inhibitors of the fibroblast growth factor receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018186710A Division JP2019019131A (ja) | 2013-10-25 | 2018-10-01 | 繊維芽細胞成長因子受容体の阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016534059A JP2016534059A (ja) | 2016-11-04 |
| JP2016534059A5 true JP2016534059A5 (enExample) | 2017-11-30 |
| JP6458023B2 JP6458023B2 (ja) | 2019-01-23 |
Family
ID=51947473
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525063A Active JP6458023B2 (ja) | 2013-10-25 | 2014-10-23 | 繊維芽細胞成長因子受容体の阻害剤 |
| JP2018186710A Pending JP2019019131A (ja) | 2013-10-25 | 2018-10-01 | 繊維芽細胞成長因子受容体の阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018186710A Pending JP2019019131A (ja) | 2013-10-25 | 2018-10-01 | 繊維芽細胞成長因子受容体の阻害剤 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9434700B2 (enExample) |
| EP (2) | EP3395814B1 (enExample) |
| JP (2) | JP6458023B2 (enExample) |
| KR (1) | KR102405452B1 (enExample) |
| CN (2) | CN110028491B (enExample) |
| AU (1) | AU2014339972B9 (enExample) |
| BR (1) | BR112016008849B8 (enExample) |
| CA (1) | CA2928042C (enExample) |
| CY (1) | CY1125393T1 (enExample) |
| DK (1) | DK3395814T3 (enExample) |
| ES (1) | ES2924111T3 (enExample) |
| HR (1) | HRP20220840T1 (enExample) |
| HU (1) | HUE059037T2 (enExample) |
| IL (1) | IL244738B (enExample) |
| LT (1) | LT3395814T (enExample) |
| MX (1) | MX2016005297A (enExample) |
| PH (1) | PH12016500739B1 (enExample) |
| PL (1) | PL3395814T3 (enExample) |
| PT (1) | PT3395814T (enExample) |
| RS (1) | RS63405B1 (enExample) |
| RU (1) | RU2704112C2 (enExample) |
| SI (1) | SI3395814T1 (enExample) |
| SM (1) | SMT202200292T1 (enExample) |
| TW (1) | TWI675828B (enExample) |
| UY (1) | UY35798A (enExample) |
| WO (1) | WO2015061572A1 (enExample) |
| ZA (1) | ZA201601971B (enExample) |
Families Citing this family (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| HUE042374T2 (hu) | 2012-06-13 | 2019-06-28 | Incyte Holdings Corp | Szubsztituált triciklusos vegyületek mint FGFR inhibitorok |
| NZ703495A (en) * | 2012-07-11 | 2018-02-23 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9663524B2 (en) | 2013-03-15 | 2017-05-30 | Celgene Car Llc | Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| CA2907243C (en) | 2013-03-15 | 2021-12-28 | Celgene Avilomics Research, Inc. | Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor |
| EP2970231A1 (en) | 2013-03-15 | 2016-01-20 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| HUE036571T2 (hu) | 2013-04-19 | 2018-07-30 | Incyte Holdings Corp | Biciklusos heterociklusok mint FGFR inhibitorok |
| US9200002B2 (en) | 2013-10-17 | 2015-12-01 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to KIT |
| HUE039268T2 (hu) | 2013-10-18 | 2018-12-28 | Eisai R&D Man Co Ltd | Pirimidin FGFR4 inhibitorok |
| AP2016009156A0 (en) | 2013-10-25 | 2016-04-30 | Novartis Ag | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
| HUE059037T2 (hu) | 2013-10-25 | 2022-10-28 | Blueprint Medicines Corp | Fibroblaszt növekedési faktor receptor gátlók |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| EP3172214B1 (en) | 2014-07-26 | 2020-05-13 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof |
| PL3200786T3 (pl) | 2014-10-03 | 2020-03-31 | Novartis Ag | Zastosowanie pochodnych pirydylowych o skondensowanym układzie bicyklicznym jako inhibitorów fgfr4 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| MX388991B (es) | 2015-02-20 | 2025-03-20 | Incyte Corp | Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr) |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| EP3283465B1 (en) | 2015-04-14 | 2021-01-06 | Eisai R&D Management Co., Ltd. | Crystalline fgfr4 inhibitor compound and uses thereof |
| WO2017011776A1 (en) | 2015-07-16 | 2017-01-19 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| WO2017019442A1 (en) | 2015-07-24 | 2017-02-02 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to kit and pdgfr |
| HK1255330A1 (zh) | 2015-08-26 | 2019-08-16 | 缆图药品公司 | 适用於治疗与ntrk相关的病症的化合物和组合物 |
| CA3003153A1 (en) | 2015-10-26 | 2017-05-04 | Loxo Oncology, Inc. | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| MX384884B (es) | 2015-11-02 | 2025-03-14 | Blueprint Medicines Corp | Inhibidores de ret. |
| WO2017087778A1 (en) | 2015-11-19 | 2017-05-26 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| WO2017161269A1 (en) | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
| MA44612B1 (fr) | 2016-04-04 | 2024-09-30 | Loxo Oncology, Inc. | Méthodes de traitement de cancers pédiatriques |
| DK3439662T3 (da) | 2016-04-04 | 2024-09-02 | Loxo Oncology Inc | Væskeformige formuleringer af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazol[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| SG11201808907PA (en) | 2016-04-15 | 2018-11-29 | Blueprint Medicines Corp | Inhibitors of activin receptor-like kinase |
| US11357769B2 (en) | 2016-05-10 | 2022-06-14 | Eisai R&D Management Co., Ltd. | Drug combinations for reducing cell viability and/or cell proliferation |
| EP3458456B1 (en) | 2016-05-18 | 2020-11-25 | Loxo Oncology Inc. | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| CN107793395B (zh) * | 2016-09-01 | 2021-01-05 | 南京药捷安康生物科技有限公司 | 成纤维细胞生长因子受体抑制剂及其用途 |
| WO2018049233A1 (en) | 2016-09-08 | 2018-03-15 | Nicolas Stransky | Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| CN106986809B (zh) * | 2016-12-02 | 2020-03-24 | 广东省微生物研究所（广东省微生物分析检测中心） | 一种5-溴-6-氯-3-吲哚辛酯的合成方法 |
| DK3524603T3 (da) * | 2016-12-19 | 2022-07-04 | Abbisko Therapeutics Co Ltd | Fgfr4-hæmmer, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf |
| CN108264511B (zh) * | 2017-01-03 | 2021-04-13 | 浙江海正药业股份有限公司 | 杂环类衍生物及其制备方法和其在医药上的用途 |
| JP6888101B2 (ja) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| CN108503593B (zh) * | 2017-02-28 | 2021-04-27 | 暨南大学 | 2-氨基嘧啶类化合物及其应用 |
| AU2018229148B2 (en) * | 2017-03-03 | 2022-08-04 | Auckland Uniservices Limited | FGFR kinase inhibitors and pharmaceutical uses |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| US11040979B2 (en) | 2017-03-31 | 2021-06-22 | Blueprint Medicines Corporation | Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR |
| CN108689878B (zh) * | 2017-04-10 | 2023-05-09 | 浙江九洲药业股份有限公司 | 光学活性二氨基衍生物的制备方法 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| JP7346420B2 (ja) * | 2017-09-05 | 2023-09-19 | バイオアーディス エルエルシー | 芳香族誘導体、その調製方法、およびその医学的適用 |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| CN111566102B (zh) | 2017-10-18 | 2023-09-08 | 缆图药品公司 | 作为激活素受体样激酶抑制剂的取代的吡咯并吡啶 |
| CN111315741B (zh) | 2017-11-01 | 2023-01-24 | 广东众生药业股份有限公司 | 一种作为fgfr4抑制剂化合物的盐型、晶型及其制备方法 |
| CN109745325B (zh) * | 2017-11-08 | 2022-02-15 | 上海翰森生物医药科技有限公司 | Fgfr4抑制剂、其制备方法和用途 |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| US11472802B2 (en) | 2018-01-18 | 2022-10-18 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors |
| US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
| EP3773589B1 (en) | 2018-04-03 | 2023-11-01 | Blueprint Medicines Corporation | Ret inhibitor for use in treating cancer having a ret alteration |
| EP3788047B1 (en) | 2018-05-04 | 2024-09-04 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| BR112020022373A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | sais de um inibidor de fgfr |
| WO2019223766A1 (zh) * | 2018-05-25 | 2019-11-28 | 上海和誉生物医药科技有限公司 | 一种fgfr抑制剂、其制备方法和在药学上的应用 |
| CN113194928A (zh) | 2018-07-31 | 2021-07-30 | 罗索肿瘤学公司 | (s)-5-氨基-3-(4-((5-氟-2-甲氧基苯甲酰胺基)甲基)苯基)-1-(1,1,1-三氟丙-2-基)-1h-吡唑-4-甲酰胺的喷雾干燥的分散体和制剂 |
| EP3849986B1 (en) | 2018-09-10 | 2022-06-08 | Array Biopharma, Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| CN110950867A (zh) * | 2018-09-27 | 2020-04-03 | 首药控股(北京)有限公司 | 一种fgfr4激酶抑制剂及其制备方法和用途 |
| WO2020063788A1 (zh) | 2018-09-27 | 2020-04-02 | 贝达药业股份有限公司 | Fgfr4抑制剂及其应用 |
| CN111138459B (zh) * | 2018-11-06 | 2022-10-18 | 南京圣和药业股份有限公司 | Fgfr4抑制剂的光学异构体及其应用 |
| WO2020119606A1 (en) * | 2018-12-10 | 2020-06-18 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of fibroblast growth factor receptor |
| WO2020131627A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| JP2022515197A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体 |
| WO2020177067A1 (en) | 2019-03-05 | 2020-09-10 | Bioardis Llc | Aromatic derivatives, preparation methods, and medical uses thereof |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| CA3136707A1 (en) | 2019-04-12 | 2020-10-15 | Blueprint Medicines Corporation | Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021023192A1 (zh) * | 2019-08-08 | 2021-02-11 | 漳州片仔癀药业股份有限公司 | 吡嗪-2(1h)-酮类化合物的a晶型和b晶型及其制备方法 |
| CN114174272B (zh) * | 2019-08-08 | 2023-05-12 | 漳州片仔癀药业股份有限公司 | 吡嗪-2(1h)-酮类化合物的制备方法 |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| KR20220100879A (ko) | 2019-10-14 | 2022-07-18 | 인사이트 코포레이션 | Fgfr 저해제로서의 이환식 헤테로사이클 |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CN112759593A (zh) | 2019-11-01 | 2021-05-07 | 北京伯汇生物技术有限公司 | 桥环并醛基吡啶衍生物及其应用 |
| WO2021088846A1 (en) * | 2019-11-04 | 2021-05-14 | Cstone Pharmaceuticals (Suzhou) Co., Ltd. | Fgfr4/pd-1 combination treatments |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
| EP4069369A4 (en) | 2019-12-06 | 2024-02-14 | Schrödinger, Inc. | CYCLIC COMPOUNDS AND METHODS OF USE THEREOF |
| CN113087696A (zh) * | 2019-12-23 | 2021-07-09 | 江苏开元药业有限公司 | 喹啉类化合物及其应用 |
| MX2022007171A (es) | 2019-12-27 | 2022-08-22 | Schroedinger Inc | Compuestos cíclicos y métodos de uso de estos. |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021190623A1 (zh) | 2020-03-27 | 2021-09-30 | 贝达药业股份有限公司 | Fgfr4抑制剂的盐型、晶型及其用途 |
| KR20230017234A (ko) | 2020-05-29 | 2023-02-03 | 블루프린트 메디신즈 코포레이션 | 프랄세티닙의 고체 형태 |
| US20230365584A1 (en) | 2020-09-10 | 2023-11-16 | Schrödinger, Inc. | Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer |
| US20230365589A1 (en) | 2020-09-18 | 2023-11-16 | Sumitomo Pharma Co., Ltd. | Novel amine derivatives |
| WO2022058838A1 (ja) * | 2020-09-18 | 2022-03-24 | 株式会社半導体エネルギー研究所 | 半導体装置、および電子機器 |
| CA3198077A1 (en) | 2020-10-05 | 2022-04-14 | Chiome Bioscience Inc. | Medicine for treating cancer |
| US20240148732A1 (en) | 2021-01-26 | 2024-05-09 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders |
| WO2022194160A1 (zh) * | 2021-03-16 | 2022-09-22 | 上海启晟合研医药科技有限公司 | 非索替尼固体形式及其制备方法 |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| US20240199625A1 (en) * | 2021-03-26 | 2024-06-20 | Hangzhou Apeloa Medicine Research Institute Co., Ltd. | Bicyclic heterocyclic fgfr4 inhibitor, pharmaceutical composition and preparation comprising same, and application thereof |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| EP4352060A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TWI896159B (zh) * | 2023-06-09 | 2025-09-01 | 大陸商上海和譽生物醫藥科技有限公司 | 一種fgfr4抑制劑組合物、其製備方法和在藥學上的應用 |
| WO2025059027A1 (en) | 2023-09-11 | 2025-03-20 | Schrödinger, Inc. | Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors |
| CN118221569A (zh) * | 2024-03-22 | 2024-06-21 | 浙江大学 | 一种环戊烷-1,2-二胺衍生物及其制备方法 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK281724B6 (sk) | 1994-11-14 | 2001-07-10 | Warner-Lambert Company | 6-arylpyrido[2,3-d]pyrimidíny, ich použitie a farmaceutické prostriedky na ich báze |
| IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| GB9708917D0 (en) | 1997-05-01 | 1997-06-25 | Pfizer Ltd | Compounds useful in therapy |
| HUP0102514A3 (en) | 1998-05-26 | 2002-03-28 | Warner Lambert Co | Pyrido-pyrimidin and pyrimido-pyrimidin derivatives as inhibitors of cellular proliferation and pharmaceutical compositions thereof |
| RU2265606C2 (ru) | 1999-10-21 | 2005-12-10 | Ф.Хоффманн-Ля Рош Аг | ГЕТЕРОАЛКИЛАМИНОЗАМЕЩЕННЫЕ БИЦИКЛИЧЕСКИЕ АЗОТСОДЕРЖАЩИЕ ГЕТЕРОЦИКЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗЫ р38 |
| US6403799B1 (en) | 1999-10-21 | 2002-06-11 | Agouron Pharmaceuticals, Inc. | Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors |
| CA2386955A1 (en) | 1999-11-22 | 2001-05-31 | Warner-Lambert Company | Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
| US6605615B2 (en) | 2000-03-01 | 2003-08-12 | Tularik Inc. | Hydrazones and analogs as cholesterol lowering agents |
| WO2002012238A2 (en) | 2000-08-04 | 2002-02-14 | Warner-Lambert Company | 2-(4-PYRIDYL)AMINO-6-DIALKOXYPHENYL-PYRIDO[2,3-d]PYRIMIDIN-7-ONES |
| US6653313B2 (en) | 2000-08-10 | 2003-11-25 | Warner-Lambert Company Llc | 1,4-dihydropyridine compounds as bradykinin antagonists |
| WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| EA007395B3 (ru) | 2002-01-22 | 2018-02-28 | Уорнер-Ламберт Компани Ллс | 2-(ПИРИДИН-2-ИЛАМИНО)ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНЫ |
| US20050009849A1 (en) * | 2003-01-03 | 2005-01-13 | Veach Darren R. | Pyridopyrimidine kinase inhibitors |
| WO2005030131A2 (en) | 2003-09-23 | 2005-04-07 | Replidyne, Inc | Bis-quinazoline compounds for the treatment of bacterial infections |
| US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| US7915259B2 (en) | 2005-01-28 | 2011-03-29 | Actelion Pharmaceuticals Ltd. | Diazabicyclononene derivatives and use thereof |
| US7906522B2 (en) | 2005-04-28 | 2011-03-15 | Kyowa Hakko Kirin Co., Ltd | 2-aminoquinazoline derivatives |
| JP2010514693A (ja) | 2006-12-22 | 2010-05-06 | ノバルティス アーゲー | Ｐｄｋ１阻害のためのキナゾリン |
| JP5442448B2 (ja) | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | Ｆｇｆｒインヒビターとしての二環式ヘテロ環式化合物 |
| US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
| EP2361248B1 (en) | 2008-06-27 | 2018-09-19 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| EP2342230A1 (en) | 2008-09-03 | 2011-07-13 | Licentia Ltd. | Materials and methods for inhibiting cancer cell invasion related to fgfr4 |
| EP2352827A4 (en) * | 2008-09-05 | 2016-07-20 | Celgene Avilomics Res Inc | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS |
| BRPI0924067A2 (pt) | 2008-12-29 | 2016-01-26 | Fovea Pharmaceuticals | compostos de quinazolina substituída |
| CA2770195C (en) | 2009-08-07 | 2015-10-13 | Chugai Seiyaku Kabushiki Kaisha | Aminopyrazole derivative |
| CN102713618B (zh) | 2009-09-16 | 2015-07-15 | 新基阿维罗米克斯研究公司 | 蛋白激酶复合物和抑制剂 |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| SG10201604074TA (en) | 2011-04-21 | 2016-07-28 | Isis Pharmaceuticals Inc | Modulation of hepatitis b virus (hbv) expression |
| JP6068451B2 (ja) | 2011-05-17 | 2017-01-25 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア | キナーゼ阻害剤 |
| FR2985257B1 (fr) | 2011-12-28 | 2014-02-14 | Sanofi Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
| PL2657233T3 (pl) | 2012-01-19 | 2015-01-30 | Taiho Pharmaceutical Co Ltd | 3,5-dipodstawiony związek alkinylobenzenowy i jego sól |
| TW201336847A (zh) * | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| NZ703495A (en) * | 2012-07-11 | 2018-02-23 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| WO2014044846A1 (en) | 2012-09-24 | 2014-03-27 | Evotec (Uk) Ltd. | 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia |
| TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
| PL3431475T3 (pl) | 2013-02-21 | 2021-09-13 | Pfizer Inc. | Stałe postacie selektywnego inhibitora CDK4/6 |
| EP2970231A1 (en) | 2013-03-15 | 2016-01-20 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| US9663524B2 (en) * | 2013-03-15 | 2017-05-30 | Celgene Car Llc | Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| US9200002B2 (en) | 2013-10-17 | 2015-12-01 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to KIT |
| HUE039268T2 (hu) | 2013-10-18 | 2018-12-28 | Eisai R&D Man Co Ltd | Pirimidin FGFR4 inhibitorok |
| AP2016009156A0 (en) | 2013-10-25 | 2016-04-30 | Novartis Ag | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
| HUE059037T2 (hu) | 2013-10-25 | 2022-10-28 | Blueprint Medicines Corp | Fibroblaszt növekedési faktor receptor gátlók |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| US9715813B1 (en) | 2014-03-02 | 2017-07-25 | Durex International Corp | Visibility electronic controller and current-based status monitor |
| US9688680B2 (en) | 2014-08-04 | 2017-06-27 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| US20160115164A1 (en) | 2014-10-22 | 2016-04-28 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| MX388991B (es) | 2015-02-20 | 2025-03-20 | Incyte Corp | Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr) |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2017019442A1 (en) | 2015-07-24 | 2017-02-02 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to kit and pdgfr |
| HK1255330A1 (zh) | 2015-08-26 | 2019-08-16 | 缆图药品公司 | 适用於治疗与ntrk相关的病症的化合物和组合物 |
| EP3365335B1 (en) | 2015-10-23 | 2024-02-14 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases |
| MX384884B (es) | 2015-11-02 | 2025-03-14 | Blueprint Medicines Corp | Inhibidores de ret. |
| WO2017087778A1 (en) | 2015-11-19 | 2017-05-26 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| WO2017161269A1 (en) | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
| SG11201808907PA (en) | 2016-04-15 | 2018-11-29 | Blueprint Medicines Corp | Inhibitors of activin receptor-like kinase |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| WO2018049233A1 (en) | 2016-09-08 | 2018-03-15 | Nicolas Stransky | Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors |
-
2014
- 2014-10-23 HU HUE18177131A patent/HUE059037T2/hu unknown
- 2014-10-23 CN CN201910274804.3A patent/CN110028491B/zh active Active
- 2014-10-23 US US14/521,909 patent/US9434700B2/en active Active
- 2014-10-23 MX MX2016005297A patent/MX2016005297A/es active IP Right Grant
- 2014-10-23 RS RS20220624A patent/RS63405B1/sr unknown
- 2014-10-23 LT LTEP18177131.2T patent/LT3395814T/lt unknown
- 2014-10-23 HR HRP20220840TT patent/HRP20220840T1/hr unknown
- 2014-10-23 SI SI201431968T patent/SI3395814T1/sl unknown
- 2014-10-23 EP EP18177131.2A patent/EP3395814B1/en active Active
- 2014-10-23 SM SM20220292T patent/SMT202200292T1/it unknown
- 2014-10-23 EP EP14802532.3A patent/EP3060560A1/en not_active Withdrawn
- 2014-10-23 JP JP2016525063A patent/JP6458023B2/ja active Active
- 2014-10-23 AU AU2014339972A patent/AU2014339972B9/en active Active
- 2014-10-23 PL PL18177131.2T patent/PL3395814T3/pl unknown
- 2014-10-23 CN CN201480058647.8A patent/CN105658642B/zh active Active
- 2014-10-23 CA CA2928042A patent/CA2928042C/en active Active
- 2014-10-23 PT PT181771312T patent/PT3395814T/pt unknown
- 2014-10-23 RU RU2016120012A patent/RU2704112C2/ru active
- 2014-10-23 BR BR112016008849A patent/BR112016008849B8/pt active IP Right Grant
- 2014-10-23 KR KR1020167012396A patent/KR102405452B1/ko active Active
- 2014-10-23 ES ES18177131T patent/ES2924111T3/es active Active
- 2014-10-23 DK DK18177131.2T patent/DK3395814T3/da active
- 2014-10-23 WO PCT/US2014/061974 patent/WO2015061572A1/en not_active Ceased
- 2014-10-23 PH PH1/2016/500739A patent/PH12016500739B1/en unknown
- 2014-10-24 UY UY0001035798A patent/UY35798A/es unknown
- 2014-10-24 TW TW103136870A patent/TWI675828B/zh active
-
2016
- 2016-03-22 ZA ZA2016/01971A patent/ZA201601971B/en unknown
- 2016-03-23 IL IL244738A patent/IL244738B/en unknown
- 2016-07-28 US US15/222,523 patent/US10221154B2/en active Active
-
2018
- 2018-10-01 JP JP2018186710A patent/JP2019019131A/ja active Pending
-
2019
- 2019-02-19 US US16/279,904 patent/US10875837B2/en active Active
-
2020
- 2020-11-24 US US17/102,628 patent/US20210347756A1/en not_active Abandoned
-
2022
- 2022-07-05 CY CY20221100453T patent/CY1125393T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016534059A5 (enExample) | ||
| RU2016120012A (ru) | Ингибиторы рецептора фактора роста фибробластов | |
| EA201991399A1 (ru) | Аминотриазолопиридиновые соединения и их применение в лечении рака | |
| EP4321513A3 (en) | Pyrrolotriazine compounds as tam inhibitors | |
| JP2018511590A5 (enExample) | ||
| EP4253366A3 (en) | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection | |
| AR102463A1 (es) | Inhibidor de cinasa aurora a | |
| EA201790246A1 (ru) | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы | |
| EA201991693A1 (ru) | Производное пиридина в качестве ингибитора ask1 и способ его получения и применения | |
| EA201001126A1 (ru) | Пирролопиримидины и пирролопиридины | |
| JP2015523383A5 (enExample) | ||
| JP2017536344A5 (enExample) | ||
| WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
| EP3954679A3 (en) | Amide compounds for the treatment of hiv infections | |
| RU2012140185A (ru) | Ингибирование ангиогенеза | |
| EA201001687A1 (ru) | Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 ) | |
| EA201892207A1 (ru) | Индолкарбоксамидные соединения | |
| JP2016526540A5 (enExample) | ||
| JP2014521688A5 (enExample) | ||
| EA201692095A1 (ru) | Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака | |
| EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| JP2017510661A5 (enExample) | ||
| RU2017112048A (ru) | Синергистические комбинации ауристана | |
| EA201592020A1 (ru) | Новая композиция для неалкогольной жировой болезни печени (нажбп) | |
| EA201692260A1 (ru) | Соединения 1,3,4-тиадиазола и их применение в лечении рака |